Sara Paltrinieri1, Stefania Fugazzaro1, Lucia Bertozzi2, Maria Chiara Bassi3, Martina Pellegrini1, Massimo Vicentini4, Elisa Mazzini5, Stefania Costi6,7. 1. Physical Medicine and Rehabilitation Unit, Azienda Unità Sanitaria Locale-IRCCS of Reggio Emilia, Viale Risorgimento 80, 42123, Reggio Emilia, Italy. 2. School of Physical Therapy, Alma Mater Studiorum, University of Bologna, Via S. Lorenzino 23, 47521, Cesena, Forlì-Cesena, Italy. 3. Medical Library, Azienda Unità Sanitaria Locale-IRCCS of Reggio Emilia, Viale Murri 9, 42123, Reggio Emilia, Italy. 4. Epidemiology Unit, Azienda Unità Sanitaria Locale-IRCCS of Reggio Emilia, Via Amendola 2, 42122, Reggio Emilia, Italy. 5. Medical Directorate, Azienda Unità Sanitaria Locale-IRCCS of Reggio Emilia, Viale Umberto I 50, 42123, Reggio Emilia, Italy. 6. Physical Medicine and Rehabilitation Unit, Azienda Unità Sanitaria Locale-IRCCS of Reggio Emilia, Viale Risorgimento 80, 42123, Reggio Emilia, Italy. stefania.costi@unimore.it. 7. Department of Surgery, Medicine, Dentistry and Morphological Sciences, University of Modena and Reggio Emilia, Reggio Emilia, Italy. stefania.costi@unimore.it.
Abstract
PURPOSE: Return to work (RTW) of cancer survivors (CSs) fluctuates in different contexts. This systematic review searched for recent data on the RTW rate of CSs in Europe, investigating associated factors. METHODS: Bibliographic search covered the period from January 2010 to February 2018, with no language restrictions. European population-based studies assessing RTW rate after cancer diagnosis were included. We excluded studies focusing on a specific cancer diagnosis. RESULTS: Twelve observational studies were selected. The cohorts investigated included 280 to 46,720 individuals from Northwestern and Central Europe diagnosed with cancer from 1987 to 2010. The median interval between diagnosis and documented RTW was 2 years (0.2-23.4 years). RTW rates of CSs ranged from 39 to 77%. RTW of individuals employed at the time of diagnosis ranged from 60 to 92%, the latter registered in a sample with good prognosis. Personal factors, work-related factors, and cancer-related factors were all associated with RTW. Healthcare team interventions facilitated reintegration to work. CONCLUSIONS: Data from Mediterranean and Central European countries are urgently needed to understand whether RTW is an issue for CSs there as well and whether socio-rehabilitative interventions are required to mitigate the potential negative impact of cancer on individuals and society.
PURPOSE: Return to work (RTW) of cancer survivors (CSs) fluctuates in different contexts. This systematic review searched for recent data on the RTW rate of CSs in Europe, investigating associated factors. METHODS: Bibliographic search covered the period from January 2010 to February 2018, with no language restrictions. European population-based studies assessing RTW rate after cancer diagnosis were included. We excluded studies focusing on a specific cancer diagnosis. RESULTS: Twelve observational studies were selected. The cohorts investigated included 280 to 46,720 individuals from Northwestern and Central Europe diagnosed with cancer from 1987 to 2010. The median interval between diagnosis and documented RTW was 2 years (0.2-23.4 years). RTW rates of CSs ranged from 39 to 77%. RTW of individuals employed at the time of diagnosis ranged from 60 to 92%, the latter registered in a sample with good prognosis. Personal factors, work-related factors, and cancer-related factors were all associated with RTW. Healthcare team interventions facilitated reintegration to work. CONCLUSIONS: Data from Mediterranean and Central European countries are urgently needed to understand whether RTW is an issue for CSs there as well and whether socio-rehabilitative interventions are required to mitigate the potential negative impact of cancer on individuals and society.
Entities:
Keywords:
Europe; Neoplasms; Return to work; Sick leave; Survivors; Systematic review literature
Authors: Corné A Roelen; Petra C Koopmans; Johan W Groothoff; Jac J van der Klink; Ute Bültmann Journal: Psychooncology Date: 2010-07-28 Impact factor: 3.894
Authors: M A Greidanus; A G E M de Boer; A E de Rijk; C M Tiedtke; B Dierckx de Casterlé; M H W Frings-Dresen; S J Tamminga Journal: Psychooncology Date: 2017-09-06 Impact factor: 3.894
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Sara Paltrinieri; Massimo Vicentini; Elisa Mazzini; Elena Ricchi; Stefania Fugazzaro; Pamela Mancuso; Paolo Giorgi Rossi; Stefania Costi Journal: Support Care Cancer Date: 2019-05-25 Impact factor: 3.603
Authors: Michiel A Greidanus; Angela G E M de Boer; Angelique E de Rijk; Sonja Brouwers; Theo M de Reijke; Marie José Kersten; Jean H G Klinkenbijl; Roy I Lalisang; Robert Lindeboom; Patricia J Zondervan; Monique H W Frings-Dresen; Sietske J Tamminga Journal: Patient Date: 2020-10 Impact factor: 3.883
Authors: Janet S de Moor; Kisha Coa; Erin E Kent; Carmen Moten; Sarah Kobrin; Cheryl Altice; K Robin Yabroff Journal: J Cancer Surviv Date: 2018-10-03 Impact factor: 4.442
Authors: Nicole L Stout; Daniel Santa Mina; Kathleen D Lyons; Karen Robb; Julie K Silver Journal: CA Cancer J Clin Date: 2020-10-27 Impact factor: 508.702
Authors: M A Greidanus; A E de Rijk; A G E M de Boer; M E M M Bos; P W Plaisier; R M Smeenk; M H W Frings-Dresen; S J Tamminga Journal: BMC Public Health Date: 2021-07-21 Impact factor: 3.295